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In the current study we examined several proteomic- and RNA-Seq-based datasets of cardiac-enriched, 
cell-surface and membrane-associated proteins in human fetal and mouse neonatal ventricular 
cardiomyocytes. By integrating available microarray and tissue expression profiles with MGI phenotypic 
analysis, we identified 173 membrane-associated proteins that are cardiac-enriched, conserved 
amongst eukaryotic species, and have not yet been linked to a ‘cardiac’ Phenotype-Ontology. To 
highlight the utility of this dataset, we selected several proteins to investigate more carefully, including 
FAM162A, MCT1, and COX20, to show cardiac enrichment, subcellular distribution and expression 
patterns in disease. We performed three-dimensional confocal imaging analysis to validate subcellular 
localization and expression in adult mouse ventricular cardiomyocytes. FAM162A, MCT1, and COX20 
were expressed differentially at the transcriptomic and proteomic levels in multiple models of mouse 
and human heart diseases and may represent potential diagnostic and therapeutic targets for human 
dilated and ischemic cardiomyopathies. Altogether, we believe this comprehensive cardiomyocyte 
membrane proteome dataset will prove instrumental to future investigations aimed at characterizing 
heart disease markers and/or therapeutic targets for heart failure.
Introduction
Cell surface or membrane proteins serve as excellent candidates and potential diagnostic and therapeutic targets 
given their importance in regulating spontaneous contractions and excitation-contraction coupling of cardi-
omyocytes1,2. Additionally, membrane proteins in the mammalian heart act as important signaling receptors, 
metabolite transporters, enzymes, cell-cell adhesion anchors, and electrical propagation regulators3. Therefore, 
a comprehensive understanding of all cardiac membrane proteins is essential to elucidate and characterize the 
physiology and pathophysiology of human heart diseases. However, in-depth analysis and identification of the 
membrane proteome of cardiomyocytes remains poorly characterized due to their hydrophobic nature and rela-
tively low abundance4.
Recent advancements in proteomic technologies have allowed significant improvements in membrane protein 
proteome discovery and topology resolution5,6. Specifically, advancements in mass spectrometry-based shotgun 
proteomics have allowed successful identification of less abundant membrane proteins, resulting in substantial 
improvements in representation of membrane proteins in proteomic datasets6–8. Therefore, identification of a 
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more complete membrane proteome in the heart has become possible and will contribute to a more detailed 
understanding of signaling networks, pathways, and protein-protein interactions in cellular biology of the heart.
At the cellular level, the molecular basis and mechanisms of impaired ventricular function in heart failure 
patients remain poorly understood. Alterations in membrane protein expression levels have been linked largely 
to depressed Ca2+ signaling and impaired relaxation in heart failure9, suggesting important functional relevance 
of membrane proteins in cardiac muscle biology, thus representing excellent therapeutic targets that modulate 
cellular signaling and function in failing cardiac muscle. To date, the majority of cardiac proteomic and bio-
chemical studies have focused on abundant soluble proteins. In this study, we carefully investigated membrane 
proteins identified previously10, incorporating publicly available microarray dataset, tissue expression profiles, 
and informatics that resulted in the identification of 173 previously uncharacterized, intrinsic cardiac-enriched 
membrane-associated proteins from human fetal and mouse neonatal ventricular cardiomyocytes. As evidence 
of the utility of this set, we applied a non-biased, systematic ranking strategy to all candidates and selected several 
highest ranked proteins to validate including FAM162A, MCT1, and COX20 as potentially novel regulators of 
cardiac function.
Results
Cardiac proteomic data analysis uncovers poorly characterized, cardiac-enriched membrane 
proteins. To identify the proteome of cell-surface/membrane associated and soluble proteins of human and 
mouse ventricular cardiomyocytes, we optimized previously the membrane enrichment of human fetal and 
mouse neonatal ventricular cardiomyocytes to enrich for cell surface, membrane, and membrane-associated 
proteins via cationic colloidal silica beads10,11. Quantitative MudPIT analysis had identified 2,762 human and 
3,033 mouse proteins with stringent filtering (<1% FDR) of peptide and protein levels. A subsequent compar-
ative QSpec proteomic analysis revealed 555 orthologue proteins were significantly enriched in the membrane 
fractions compared to the membrane-depleted counterpart. A recent update of gene names realigned the data 
to 550 proteins since 5 protein IDs were amalgamated with existing protein accessions (Fig. 1a). Our earlier 
studies focused on two of these proteins, TMEM65 and REEP5, in detailed biochemical analyses, identifying 
their specific roles in regulating cardiac conduction and cardiac muscle sarcoplasmic reticulum organization and 
function, respectively10,12. Here, we performed a detailed analysis of all 550 identified cardiac membrane proteins 
and showed that GO term-associated classifications demonstrated 50% of the identified protein clusters had a 
predicted transmembrane domain and 60% of them contained the GO term “membrane” (Fig. 1b). Moreover, 
70% of the 550 protein clusters were classified as cell surface-associated proteins and only 20% of them were 
linked to known cardiac phenotype ontologies based on available forward genetics studies in mice in the MGI 
database (Fig. 1b). All 550 proteins were each scored and ranked on a set of non-biased, defined criteria (Fig. 1c 
and full ranking criteria listed in Supplemental Table 1) to prioritize proteins that had no previous association to 
cardiac function and were enriched >3-fold within cardiac tissue compared to other tissues, according to pub-
licly available microarrays (Supplemental Table 1; individual worksheets represent rank ordered analysis of the 
550 membrane associated protein clusters in various subcellular domains). Based on this analysis, this strategy 
resulted in 173 of these membrane-associated proteins that would be classified as previously uncharacterized, 
cardiac-enriched membrane-associated proteins. Hierarchical clustering of the 550 membrane-associated protein 
clusters demonstrated distinct clusters of cardiac enrichment across various healthy human tissues (Supplemental 
Fig. 1a).
We next mapped these 550 membrane enrichment proteins to the Human Protein Atlas ‘Membrane 
Proteome’; where approximately 28% of all human protein coding genes are predicted to harbor at least one 
transmembrane domain (Fig. 1d). This analysis showed that 154 of our identified cardiac-enriched membrane 
proteins were present in the Membrane Proteome, leaving 396 out of the 550 protein clusters potentially novel 
membrane protein products. Similarly, we compared our list of 550 proteins against recent studies of whole tissue 
lysates from monkey heart proteome by Hu et al.13 and the human heart proteome by Doll et al.14 (Fig. 1e). Of 
note, 229 cardiac-enriched membrane proteins were also identified in both of these studies with 12 unique pro-
teins identified only in our analysis (Fig. 1e).
Next, we assessed the organelle distribution of all “membrane-associated” candidates identified by our pro-
teomics and informatics analyses. We analyzed their subcellular localizations based on their Gene Ontology cel-
lular component (GOCC) classification (Fig. 1f) and observed that 228/550 (41%) of all candidate proteins were 
identified as mitochondrial in origin which was expected as cardiomyocytes are highly oxidative and metabolically 
active. Interestingly, 125/550 (23%) of identified membrane-associated proteins were classified as localized to 
the nucleus, likely suggesting the dynamic roles of nuclear membrane proteins in regulating gene expression, 
cell mobility, and DNA damage repair in cardiomyocytes15,16 (Fig. 1f). Moreover, 63/550 (12%) of the 550 mem-
brane associated protein clusters identified were classified as ‘cell surface’ or ‘plasma membrane’ in origin and 
another 65/550 (12%) were attributed to other organelles including the endoplasmic reticulum, golgi apparatus, 
peroxisomes, and lysosomes. Interestingly, of much less abundance, 6% (32/550) and 4% (22/550) of protein clus-
ters were classified as cytosolic or proteins in the secretory pathway, respectively, suggesting the identification 
of membrane-associated cytosolic and secreted proteins in our proteomic analysis. However, it is important to 
acknowledge that Gene Ontology classification has limitations, further detailed biomolecular studies obviously 
would be needed to determine precise subcellular localization and function in the cell.
Identification of organelle-specific, previously uncharacterized cardiac membrane proteins. 
Next, we aimed to identify highly scored cardiac-enriched protein clusters that have not been investigated to date 
in the heart across various organelles in the myocyte. Based on previous GOCC classification, we had identified 
228 mitochondrial membrane proteins, 125 nuclear membrane proteins, 63 plasma membrane associated pro-
teins, 65 ER, golgi apparatus, peroxisome, lysosome-associated membrane proteins, 32 cytosolic, and 22 secreted 
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membrane associated proteins (Fig. 1f). Our bioinformatic analysis (Fig. 2) showed that 155 (68%) mitochondrial 
membrane-associated proteins were at least 3-fold enriched within cardiac tissue according to publicly available 
BioGPS microarrays; 130 of which were further classified as ‘novel’ cardiac membrane proteins with no previously 
reported MGI cardiac related phenotype. Similarly, 10% of all identified nuclear membrane associated proteins 
were found cardiac-enriched by BioGPS, and 6 of the 13 cardiac-enriched nuclear membrane associated proteins 
were reported with no previous MGI heart related phenotype (Fig. 2b).
Detailed analysis of the plasma membrane-associated protein clusters in Fig. 2c showed that 39 (62%) of 
which were found 3-fold enriched within cardiac tissue, 15 of these were further classified as novel PM related 
cardiac-enriched membrane proteins with no phenotype ontology. Similar informatic analysis of ER, golgi 
apparatus, peroxisome, and lysosome-related membrane proteins showed that 16 (25%) organellar proteins 
were considered cardiac-enriched, 10 of which were further classified as novel cardiac-enriched organellar 
membrane-associated proteins with no previous reported cardiac phenotype (Fig. 2d). Interestingly, AFR3 was 
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Fig. 1 Membrane proteomic analysis of human fetal and murine ventricular cardiomyocytes. (a) Schematic 
diagram of experimental workflow that resulted in the identification of 550 membrane-enriched protein 
clusters in human and mouse cardiomyocytes. (b) Heatmap depicting Gene Ontology (GO) term associated 
distribution and cardiac/heart phenotype ontologies of the 550 membrane-enriched protein clusters. 
(c) Schematic diagram of the ranking strategy applied to the 550 protein clusters to identify previously 
uncharacterized cardiac-enriched membrane proteins. (d) Venn diagram depicting overlap of protein coverage 
between our membrane-enriched proteome from human and mouse ventricular cardiomyocytes and the 
Human Protein Atlas Membrane Proteome. (e) Venn diagrams depicting overlap of protein coverage between 
our membrane-enriched proteome from human and mouse ventricular cardiomyocytes and the monkey 
(Rhesus macaque) heart proteome from Hu et al.13 and human heart proteome from Doll et al.14. (f) Distribution 
of the 550 membrane-enriched protein clusters across various subcellular organelles based on their GO cellular 
component classification. Detailed ranking criteria and step-by-step ranking of all candidates were uploaded to 
figshare (https://doi.org/10.6084/m9.figshare.11844972.v12).
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solely identified in our membrane proteomic analysis of human and mouse cardiomyocytes. Additionally, 14 
(44%) cytosolic and 13 (59%) secreted protein clusters were found to be cardiac-enriched (Fig. 2e,f). Specifically, 
7 cytosolic membrane-associated proteins had no previously reported MGI heart related phenotype, and 5 
secreted membrane-associated proteins were found with no reported MGI heart phenotype.
Next, tissue-wide transcriptomic analysis of these previously uncharacterized, cardiac-enriched membrane 
proteins was performed across non-diseased human tissues. Specifically, we employed mRNA transcript data 
from the Human Proteome Map17 and showed dominant cardiac expression across various organ tissues for 
each organellar classification (Fig. 3). Specifically, the gene level expression matrix was downloaded and nor-
malized to total expression across all tissues17. Figure 3a shows predominant mRNA expression in the fetal and 
adult heart of most of the 130 mitochondrial related membrane proteins. Notably, COQ3, NDUFB8, NDUFB11, 
PDHB, ATP5D, APOOL, PDK1, and CPT1B showed nearly exclusive expression in the heart. Moreover, domi-
nant cardiac expression of MRL4, MRPS31, and PDK1 in the fetal heart compared to adult heart was observed. 
Conversely, expression of SUCLG1, SUCLG2, SDHA, COQ3, NDUFA3, and NDUFB4 was seen in the adult heart 
compared to fetal heart (Fig. 3a). Heat maps of the plasma membrane proteins showed proteins such as MCT1, 
DYSF and SORBS1 were enriched in the heart with some expression across the other tissues while OBSCN was 
detected only in the heart (Fig. 3b). Analysis of the 10 organellar (ER, golgi, peroxisomes, lysosomes) (Fig. 3c), 7 
cytosolic (Fig. 3d), 6 nuclear (Fig. 3e), and 5 secreted (Fig. 3f) membrane-associated proteins showed transcript 
expression across various healthy human tissues. Notably, SYNPO2L, MYOM1, MYL3 showed restricted expres-
sion to only the cytosol in the heart (Fig. 3d). However, it is important to acknowledge that transcriptomic data 
must be interpreted carefully due to the poor correlation between mRNA expression level and the abundance of 
its associated protein product. To circumvent this issue, we applied a defined set of non-biased criteria to prior-
itize the candidate proteins for follow-up experiments (Supplemental Table 1). This strategy equally evaluated 
each criterion in our rank-ordered analysis of all candidates and resulted in a total of 18 highest ranked mem-
brane proteins where existing data demonstrated their subcellular localization to both human and mouse cardio-
myocyte membranes in the cell with no previous connection to cardiac function, and are least 3-fold enriched in 
the heart (Supplemental Table 1). Interestingly, many of the abovementioned cardiac preferential proteins were 
not among the 18 highest ranked candidate proteins due to non-membrane subcellular localization and/or pre-
vious association with cardiac function. These cardiac enriched proteins are quite likely of great interest in future 
Fig. 2 Analysis of cardiac membrane proteins within various subcellular domains. Consort diagrams 
showing classification of the 550 membrane-enriched protein clusters and analyses of cardiac enrichment 
and phenotypic novelty based on publicly available BioGPS microarray data and MGI phenotypic analysis, 
respectively in (a) mitochondrion, (b) nucleus, (c) plasma membrane, (d) other organelles (ER, golgi apparatus, 
peroxisomes, lysosomes), (e) cytosol, and (f) the secretory pathway.
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Fig. 3 Transcriptomic analysis of novel cardiomyocyte-enriched membrane proteins shows cardiac enrichment 
across various tissues. Heatmaps showing mRNA transcript levels of 173 novel cardiac-enriched membrane 
proteins across clinically defined healthy human tissues; mRNA transcript data were obtained from Human 
Proteome Map and are presented according to their subcellular classifications in (a) mitochondrion, (b) plasma 
membrane, (c) other organelles (ER, golgi apparatus, peroxisomes, lysosomes), (d) cytosol, (e) nucleus, and (f) 
the secretory pathway. All source data input and normalized output files were uploaded to figshare (https://doi.
org/10.6084/m9.figshare.11844972.v12).
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studies to further our understanding of their precise role in heart, although they did not reach a high enough 
criterion weighting in our particular evaluation.
Nevertheless, transcriptomic analysis of the 67 cardiac-enriched membrane associated proteins with previous 
MGI cardiac phenotype further demonstrated the utility and potential of our dataset (Supplemental Fig. 2a–f). 
Specifically, mutations in cell surface protein DSC2 have been linked to arrhythmogenic and hypertrophic car-
diomyopathies18–21 while POPDC2 has been shown to be essential for heart muscle development22,23. Deletion of 
cardiac cytosolic protein CTNNA3 in the mouse has been associated with dilated cardiomyopathy and actomyo-
sin dysregulation in the heart24,25. Lastly, detailed transcriptomic breakdown of the non-cardiac-enriched protein 
distributions were also analyzed and shown in Supplemental Figs. 3, 4a–f for comparison.
FAM162A, MCT1, and COX20 are evolutionarily conserved, cardiac ventricular-enriched membrane 
proteins. To further assess the subcellular localization of the 173 ranked candidates in each subcellular orga-
nelle in the heart, we utilized immunohistochemical data in the Human Protein Atlas26 to investigate their protein 
distributions and expression patterns in healthy human ventricular tissues (Fig. 4). Specifically, relative protein 
expression was obtained through the reported human heart muscle immunohistochemical images available at 
the Tissue Atlas. For these studies, we selected the highest ranked proteins in each subcellular organelle classi-
fication (Supplemental Table 1) and, where available, obtained human immunohistochemical images from the 
HPA. Using this approach, as expected COX20 and FAM162A showed localization to mitochondria of cardio-
myocytes with strong mitochondrial expression patterns throughout the sections. Similarly, TMEM65, MCT1, 
SLC12A7, TLN2, MSN, FLOT1, SNTA1, DYSF, and AOC3 showed localization to the membranes of cardiomyo-
cytes with particularly strong expression at cell surface and the cardiac intercalated disks. Immunohistochemistry 
analysis of REEP5 showed moderate expression and localization to the ER throughout the cells. Furthermore, 
STOM and CTNND1 revealed localization to the cytosolic space of cardiomyocytes. Similarly, LAMA2, LAMB2, 
and BGN showed subcellular localization throughout the cells perhaps in the protein secretory pathway. 
Immunohistochemistry analysis of MYH7, TNNT2, and TNNI3 were included as positive controls and demon-
strated very strong, sarcomeric expression patterns and localization to cardiac muscle fibers in these healthy 
human ventricular tissues (Fig. 4).
As evidence of the utility of this refined dataset, we selected several highly ranked cardiac-enriched 
membrane-associated proteins to determine their protein expression across mouse tissues including FAM162A, 
MCT1, and COX20. We selected FAM162A, MCT1 and COX20 as prioritized candidates of novel proteins based 
TMEM65 (PM) MCT1 (PM)COX20 (Mito)
TLN2 (PM)
SLC12A7 (PM)
MYH7 (Sarcomere) TNNT2 (Sarcomere) TNNI3 (Sarcomere)
STOM (Cytosol)REEP5 (ER)
FAM162A (Mito)
MSN (PM) FLOT1 (PM) SNTA1 (PM)
CTNND1 (Cytosol)
DYSF (PM)
LAMA2 (Secreted)AOC3 (PM)
LAMB2 (Secreted) BGN (Secreted)
Fig. 4 Immunohistochemistry analysis of top ranked cardiac-enriched candidates. Immunohistochemistry 
analysis of the top ranked candidates in each subcellular classification (Mitochondrion, plasma membrane, 
other organelles (ER, golgi apparatus, peroxisomes, lysosomes), cytosol, and the secretory pathway in healthy 
human ventricular tissues from the Human Protein Atlas. Immunohistochemical stain intensity was assessed 
independently as either weak, moderate or strong and reported as protein expression score (PES). COX20, 
moderate PES; FAM162A, weak PES; Tmem65, moderate PES; MCT1, moderate PES; SLC12A7, moderate PES; 
TLN2, moderate PES; MSN, moderate PES; FLOT1, moderate PES; SNTA1, moderate PES; DYSF, moderate 
PES; AOC3, negative PES; REEP5, moderate PES; STOM, weak PES; CTNND1, moderate PES; LAMA2, strong 
PES; LAMB2, strong PES; BGN, moderate PES; MYH7, strong PES; TNNT2, strong PES; TNNI3, strong PES. 
Scale bar, 25μm. All images shown are representative of approximately 5 distinct regions of interest (ROIs) 
assessed per sample, n = 3 independent patient tissue blocks.
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on their highly muscle-specific tissue profiles along with MGI phenotypic analysis, representing the next logi-
cal targets for detailed follow-up biomolecular studies. In addition to the phenotypic analysis using the mouse 
genome informatics data, no known human mutations of FAM162A, MCT1, and COX20 have been linked 
to classical human heart diseases. To corroborate previous mRNA tissue expression analysis of FAM162A, 
MCT1, and COX20, immunoblot analysis of diverse adult mouse tissues (whole heart, ventricle, atria, whole 
brain, stomach, kidney, skeletal muscle) demonstrated strong protein expression in the whole heart in the heart 
for FAM162A (Fig. 5a), MCT1 (Fig. 5b), and COX20 (Fig. 5c). Notably, while FAM162A, MCT1, and COX20 
demonstrated ventricular muscle enrichment, abundant expression of MCT1 was also detected in the atria and 
skeletal muscle (Fig. 5b). To examine antibody specificity against FAM162A, MCT1, and COX20, HEK overex-
pressed cMyc/DDK-tagged human FAM162A, MCT1, and COX20 purified lysates were obtained (Fig. 5a–c, left 
panels) for subsequent immuno-competition assays. For these experiments regarding FAM162A, immunoblot 
analysis of the HEK overexpressed human FAM162A lysate showed a clear doublet of FAM162A ~17 and 20 kDa. 
However, in the mouse tissues, higher molecular weight species of FAM162A were observed ~25, 35 and 48 kDa 
(Fig. 5a); although the implications of the potential oligomeric/altered status of FAM162A remains to be eluci-
dated. Nonetheless, a clear enrichment of FAM162A antibody reactivity in striated muscle in the heart and skel-
etal muscle was apparent. Importantly, immunodepletion of the bands in the immunoblots using the FAM162A 
overexpression lysate demonstrated reduced intensity of bands observed at 17, 25, 35 and 48 kDa across all tissues 
indicating some degree of specificity of the reactivity (Fig. 5a, middle panel). MCT1 showed much cleaner anti-
body reactivity with a clear single band at ~42 kDa (predicted size) across nearly all tissues (Fig. 5b, top panels) 
that showed immunodepletion using purified cMyc/DDK-tagged MCT1 lysate, as the 42 kDa bands showed sig-
nificant reduction in intensity (Fig. 5b, middle panel). The COX20 reactivity showed multiple band reactivity at 
13 (predicted correct size), 25, 50, 58, 60 and 65 kDa (Fig. 5c, top panels). Immunodepletion using purified cMyc/
DDK-tagged COX20 lysate was successful, as the multitude of bands visualized showed significant reduction in 
intensity under the competition conditions (Fig. 5c, middle panel). Lastly, immunoblot analysis of FAM162A, 
MCT1, and COX20 in isolated cardiac cytosolic fraction and microsomes showed a clear enrichment of MCT1 
and COX20 in enriched membrane fractions (microsomes), along with the presence of FAM162A (Fig. 5d, left 
panels). While COX20 and MCT1 were not detected in the cytosolic fraction, FAM162A showed abundant 
expression also in this fraction. Control immunoblots were performed using calnexin (ER-enriched membrane 
protein enriched in microsomes), α-tubulin (cytosolic protein), sodium-calcium exchanger (NCX1; plasma 
membrane protein), and COXIV (inner mitochondrial membrane protein) (Fig. 5d, right panels) demonstrated 
successful subcellular fractionation of cardiac cytosolic and membrane fractions.
Given the identification of all three of these proteins in both human and mouse cardiomyocyte membrane 
proteomic isolations, we performed a detailed multi-species amino acid sequence analysis of FAM162A, MCT1, 
and COX20, with each of the three candidates exhibited a high degree of conservation throughout eukaryotic 
evolution. Specifically, FAM162A showed 79% homology between human and mouse FAM162A and 65% peptide 
conservation throughout evolution (Supplemental Fig. 5a). FAM162 is a family of proteins consisting two mem-
bers, FAM162A and FAM162B. Our phylogenetic analysis demonstrated two distinct clustering of mammalian 
FAM162, demonstrating two diverse evolutionary descents within the FAM162 family (Supplemental Fig. 5b). 
Our RNA-Seq analysis of the FAM162 family further demonstrated that FAM162A shows dominant expression 
across various tissues in the FAM162 family (Supplemental Fig. 5c).
MCT1 exhibited 86% homology between human and mouse MCT1 and 78% peptide conservation through-
out evolution (Supplemental Fig. 6a). MCT1 belongs to proton-linked monocarboxylate transporters consisting 
of a family of 14 members within the MCT family of proteins as demonstrated by our phylogenetic analysis yield-
ing 14 distinct clustering of mammalian taxa (Supplemental Fig. 7a). While the expression distribution of MCT 
isoforms has been shown to be organism and tissue specific, our RNA-Seq analysis of various tissues showed that 
MCT1 is the predominant MCT in both the fetal and adult heart (Supplemental Fig. 7b)27.
Lastly, from zebrafish to mouse to monkey to human, COX20 demonstrated 81% homology between human 
and mouse COX20 and 69% peptide conservation throughout eukaryotic evolution (Supplemental Fig. 5d).
FAM162A, MCT1, and COX20 transmembrane sequence prediction and membrane topology. 
We explored human membrane topology using a multi-algorithm prediction tool (TOPCONS) based on available 
peptide sequences. We showed that a consensus FAM162A membrane topology model exhibited one transmem-
brane domain region with the N-terminus region residing in the inter mitochondrial membrane space and the 
C-terminus in the cytosol (Fig. 6a,d). Membrane topology and hydrophobicity prediction analyses of human 
MCT1 have proposed a structure with eleven transmembrane domains with the N-terminus in the extracellular 
space and the C-terminus in the cytosol as well as a large internal cytoplasmic loop between TM5 and TM6 
(Fig. 6b,e). This prediction is consistent with the knowledge that MCTs possess ten to twelve transmembrane 
domains. However, structural labeling and proteolytic digestion studies of rat MCT1 has been shown to possess 
a total of twelve transmembrane domains with both N- and C-termini within the cytosol28. Lastly, our consensus 
membrane topology analysis of human COX20 confirmed two transmembrane domains with the hydrophilic 
domains of COX20 in the mitochondrial intermembrane space (Fig. 6c,f), consistent with the literature.
FAM162A, MCT1, and COX20 endogenous expression and localization in cardiac myocytes. 
We next performed immunofluorescence analysis of endogenous expression pattern in primary cultured neonatal 
mouse ventricular cardiomyocytes and isolated adult mouse ventricular cardiomyocytes for FAM162A, MCT1, 
and COX20. FAM162A demonstrated typical mitochondrial staining pattern in cultured neonatal cardiomyocytes 
(Fig. 7a) and a very organized mitochondrial staining pattern in isolated adult mouse cardiomyocytes (Fig. 7b). 
MCT1 showed clear localization to the plasma membrane in cultured neonatal mouse ventricular cardiomyocytes 
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Fig. 5 Immunblot analysis of protein expression across multiple tissues and microsomal fractions. Immunoblot 
analysis of (a) FAM162A, (b) MCT1, and (c) COX20 protein expression levels in mouse tissues. Blots were 
incubated with either anti-DDK antibody or FAM162A, MCT1 or COX20. Immunodepletion experiments 
were carried out by incubating primary antibodies together with HEK overexpression lysates. Coomassie blue 
gels were performed to visualize protein loading across all samples. (d) Immunoblot analysis of FAM162A, 
MCT1, and COX20 in isolated adult cardiac cytosolic fraction and enriched membrane microsomes from 10 
mouse hearts. Blots were probed with primary antibodies as indicated, and in parallel, samples were run on 
a Coomassie blue gel. All immunoblots shown are representative of 3 total immunoblots performed, n = 3 
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Fig. 6 Membrane topology and prediction analysis of FAM162A, MCT1, and COX20. (a–c) Prediction of 
human FAM162A, MCT1, and COX20 protein topography generated by TOPCONS (http://topcons.cbr.
su.se). (d–f) Predicted membrane topology model of human FAM162A, MCT1, and COX20A generated by 
independent biological replicates. Original uncropped immunoblots are provided in Supplemental Fig. 9. All 
original uncropped images were uploaded to figshare (https://doi.org/10.6084/m9.figshare.11844972.v12).
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and isolated adult mouse cardiomyocytes (Fig. 7a,b). Endogenous COX20 expression exhibited characteristic 
mitochondrial staining patterns in cultured neonatal mouse ventricular cardiomyocytes and isolated adult mouse 
cardiomyocytes (Fig. 7a,b) similar to FAM162A patterns. To validate the specificity of the staining patterns, our 
immunodepletion assays using cMyc/DDK-tagged FAM162A, MCT1, and COX20 lysates successfully masked 
the specific signals shown in Fig. 7b top panels in cardiomyocytes. Additionally, three-dimensional reconstructive 
analysis of our confocal data was performed in the isolated adult cardiomyocytes for all three proteins. FAM162A 
and COX20 showed longitudinal cardiac mitochondria as well as localization between rows of myofibrils (Fig. 7c). 
Three-dimensional reconstructive analysis of endogenous MCT1 expression in isolated adult mouse cardiomyo-
cytes showed strong expression in the plasma membrane and cardiac intercalated disks (Fig. 7c).
To further corroborate the specificity of the staining patterns, we performed immunofluorescence co-staining 
analysis of FAM162A with COX IV, a known mitochondrial membrane marker, and demonstrated a high 
degree of co-localization in the mitochondria in isolated adult mouse cardiomyocytes (Fig. 8a, left panels and 
Supplemental Fig. 8a). Three-dimensional reconstructive analysis confirmed significant, strong co-localization 
of FAM162A (Pearson coefficient of 0.76 ± 0.16; p < 0.05) with COX IV in adult cardiomyocytes (Fig. 8a, right 
panels). Next, we compared the expression of MCT1 with that of a known plasma membrane protein, G protein 
inhibitory alpha subunit (Gαi) which demonstrated strong expression of both MCT1 and Gαi in their respec-
tive subdomains in the plasma membrane and MCT1 in the intercalated disks of cardiomyocytes (Fig. 8b and 
Supplemental Fig. 8b). Three-dimensional reconstructive analysis further demonstrated strong co-localization 
between MCT1 and Gαi at the plasma membrane (Pearson coefficient of 0.53 ± 0.03; p < 0.05) (Fig. 8b). Lastly, 
immunofluorescence analysis of COX20 co-stained with a mitochondrial marker, COX IV, demonstrated strong 
subcellular mitochondrial co-localization throughout the cell (Pearson coefficient of 0.61 ± 0.12; p < 0.05) (Fig. 8c 
and Supplemental Fig. 8c).
Differential regulation of FAM162A, MCT1, and COX20 protein expression within the myocar-
dium of heart failure patients. To assess for any correlation to cardiac disease, we performed a query of 
publicly available GEO RNA-Seq datasets containing data for human and mouse cardiovascular diseases to deter-
mine expression levels of FAM162A, MCT1, and COX20. Specifically, FAM162A transcript levels were upreg-
ulated in several mouse disease models including transverse aortic constriction-induced (TAC) heart failure, 
myocardial infarction, and hypertrophic cardiomyopathy (Fig. 9a). Consistent with the mouse data, an increased 
expression of FAM162A was observed in human dilated cardiomyopathy (DCM), idiopathic cardiomyopathy, 
and ischemic cardiomyopathy (ICM), albeit not significantly. Interestingly, MCT1 transcript levels changed 
uniquely in human heart diseases. While a relatively inconsistent trend of MCT1 expression levels was observed 
with several mouse disease models, a marked reduction in MCT1 transcript levels were detected in human idio-
pathic and ischemic cardiomyopathies, perhaps suggesting a link in ICM disease progression (Fig. 9b). Similarly, 
decreased levels of COX20 transcripts were observed in mouse TAC, infarcted, and hypertrophic hearts (Fig. 9c). 
In agreement with these data, human DCM and idiopathic cardiomyopathy also showed a downregulation of 
COX20 expression, albeit not significantly (Fig. 9c). However, we acknowledge that these data are observational 
in nature and do not establish a causal or direct link between the altered expression and cardiac dysfunction.
In an attempt to establish the link between altered expression and human heart diseases, we performed immu-
noblot analysis of FAM162A, MCT1, and COX20 to investigate protein levels in human hearts from patients with 
clinical DCM and ICM, the two most common etiologies of heart failure. Patient baseline data and clinical char-
acteristics are reported in Table 1. We first compared their expression levels in human DCM and ICM myocardial 
tissues to non-failing myocardial controls (NFC). Protein levels of FAM162A were found significantly elevated 
in DCM and to a greater extent in ICM hearts; whereas MCT1 and COX20 expression levels were significantly 
reduced in ICM hearts only (Fig. 10a). A near complete depletion of MCT1 expression in ICM hearts, but not 
DCM hearts, showed apparent disease-specific changes in the expression levels of MCT1 and may provide func-
tional insights to ICM-induced heart failure (Fig. 10a). MCT1 has been reported at 40–48 kDa in previous studies 
in human muscle tissues29,30, and consistent with the literature, we detected molecular bands of MCT1 at 42 kDa. 
The presence of a higher molecular weight band (~52 kDa) across all our human blots was suspected to be IgG. 
Next, assessment of protein expression in the distinct regions of the left ventricular myocardium of ICM patients 
was performed using myocardial tissues from infarct, peri-, and non-infarct regions of the left ventricle to explore 
intra-cardiac differences (Fig. 10b). Markedly elevated FAM162A protein expression levels were measured in the 
dynamic remodeling region of the peri-infarct relative, and levels were nearly absent in the infarct zone which 
is composed of fibrotic scar mostly (Fig. 10b). Furthermore, the relatively low MCT1 expression in ICM hearts 
compared to NFC and DCM hearts was shown to be consistent within the whole left ventricle of ICM hearts, 
whereas decreased COX20 protein levels appeared to be restricted to the infarct region (Fig. 10b). These data 
demonstrate that FAM162A upregulation occurred in both models of heart failure, and that MCT1 and COX20 
decreased levels occurred in ICM, suggesting perhaps distinct roles for these protein candidates. However, two 
major limitations for consideration when evaluating human samples are the heterogeneous cell populations and 
inter-individual variability which may have resulted in altered expression ratios observed in our study. Future 
investigations with a larger patient sample size and follow-up biochemical studies in isolated cardiomyocytes are 
required to corroborate and extend these initial findings.
modification of a T(E)Xtopo output. Peptide immunogen sequences for commercially available FAM162A, 
MCT1, and COX20 antibodies used in the current study are indicated by an antibody icon.
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Fig. 7 Immunofluorescence analysis of FAM162A, MCT1, and COX20 expression in mouse neonatal and adult 
ventricular cardiomyocytes. (a) Immunofluorescence analysis of endogenous FAM162A, MCT1, and COX20 
expression (green) in isolated mouse neonatal ventricular cardiomyocytes. Nuclear staining was visualized with 
Hoechst staining (blue). Scale, 10μm. (b) Confocal imaging of endogenous FAM162A, MCT1, and COX20 
expression (green) in isolated adult mouse ventricular cardiomyocytes demonstrate striated mitochondrial 
staining patterns for FAM162A and COX20, and exclusive plasma membrane localization of MCT1. Lower 
panels, imaging experiments were carried out by incubating reaction mixes of the primary antibodies with their 
respective overexpression protein lysates prior to incubating overnight. Scale, 20μm. (c) Three-dimensional 
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Discussion
The process of cardiac contraction is precisely controlled by many essential membrane proteins to generate elec-
trical signals and mechanical forces needed to pump the heart. For this reason, membrane biology is perhaps 
the most important, yet most difficult to study in cell biology due to poor solubility and relatively low expression 
of this class of protein. Here, we used quantitative mass spectrometry data, informatics and imaging analysis of 
human and mouse cardiomyocyte to investigate these cardiac-relevant, membrane proteins. We identified 173 
membrane-associated proteins as a result of this analysis. We have provided further compelling evidence suggest-
ing that some of our prioritized rank-ordered list of proteins, including FAM162A, MCT1, and COX20 are car-
diac enriched, localized within subcellular compartments, and may play a role in the progression of heart failure.
While FAM162B has been linked to congenital colon disease as a result of lacking nerve cells in the colon31, 
FAM162A has been shown to function as a pro-apoptotic molecule involved in facilitating hypoxia-induced 
adult mouse ventricular cardiomyocytes 3D reconstruction
MERGE
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a
adult mouse ventricular cardiomyocytes 3D reconstructionb
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Fig. 8 Co-immunofluorescence analysis demonstrates colocalization of FAM162A and COX20 with known 
mitochondrial marker, COXIV, and MCT1 colocalization with known plasma membrane protein, Gαi, in 
isolated adult mouse cardiomyocytes. (a) Immunofluorescence analysis of FAM162A (green) co-stained with 
mitochondrial protein, COXIV (red) in acutely isolated adult mouse cardiomyocytes. Three-dimensional 
reconstructive analysis demonstrates regions of colocalization (yellow) with a Pearson’s coefficient p > 0.5. 
Scale, 10 μm. (b) Immunofluorescence analysis of MCT1 (green) co-stained with known plasma membrane 
protein, Gαi (red) in acutely isolated adult mouse cardiomyocytes. Three-dimensional reconstructive 
analysis demonstrates regions of colocalization (yellow) with a Pearson’s coefficient p > 0.5. Scale, 10μm. (c) 
Immunofluorescence analysis of COX20 (green) co-stained with mitochondrial protein, COXIV (red) in 
acutely isolated adult mouse cardiomyocytes. Three-dimensional reconstructive analysis demonstrates regions 
of colocalization (yellow) with a Pearson’s coefficient p > 0.5. Scale, 10μm. Nuclear staining was visualized with 
Hoechst staining (blue). All images shown are representative of approximately 30–40 total images captured per 
condition, n = 3 independent biological replicates. All original uncropped microscopy images were uploaded to 
figshare (https://doi.org/10.6084/m9.figshare.11844972.v12).
reconstructive analysis using Imaris (Oxford Instruments) highlights the endogenous expression patterns 
of FAM162A, MCT1, and COX20. All images shown are representative of approximately 30–40 total images 
captured per condition, n = 3 independent biological replicates. All original uncropped microscopy images were 
uploaded to figshare (https://doi.org/10.6084/m9.figshare.11844972.v12).
13Scientific Data |           (2020) 7:425  | https://doi.org/10.1038/s41597-020-00762-1
www.nature.com/scientificdatawww.nature.com/scientificdata/
mitochondrial apoptosis32,33. Specifically, in vitro overexpression of FAM162A induces canonical mitochondrial 
cell death in prostatic cancer cells and human alveolar epithelial cells. More excitingly, FAM162A targeted sup-
pression has been shown to attenuate apoptosis, demonstrating its anti-apoptosis potential for potential alterna-
tive therapeutic strategy32,34. However, the specific role and detailed subcellular localization of FAM162A in the 
myocyte in the heart has not been explored.
MCT1 is best known as a proton-coupled monocarboxylate transporter that mediates the transport of many 
monocarboxylates such as lactate, pyruvate, ketone bodies, and various amino acids across the plasma membrane. 
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Fig. 9 GEO transcriptomic analysis of FAM162A, MCT1, and COX20 mRNA transcript levels in various 
mouse and human heart diseases. (a–c) GEO RNA profiles demonstrate alterations in FAM162A, MCT1, 
and COX20 expression across various mouse and human heart diseases. Data are reported as normalized 
hybridization signals. Red bars indicate increased expression against normal hearts, blue bars indicate decreased 
expression against normal hearts, n = 3–5 available biologically independent measurements. Asterisks indicate 
a statistically significant p value in a Tukey’s multiple comparison analysis where *p < 0.05 and **p < 0.01; data 
are presented as mean ± SEM. All source data input and analyzed output files were uploaded to figshare (https://
doi.org/10.6084/m9.figshare.11844972.v12).
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The regulation of these small molecules contributes to a multitude of metabolic pathways during normal physio-
logical as well as pathological conditions. The molecular function of MCT1 and its importance for normal phys-
iological metabolism have been characterized, previously35. However, considerably less information is available 
regarding the precise role of MCT1 in cardiac metabolism under normal and pathological conditions. In heart 
failure, a metabolic shift in energy substrate is established, favoring carbohydrate utilization as well as increased 
lactate transport to improve heart function in response to an insult36. In fact, increased MCT1 expression in a 
rat model of myocardial infarction and congestive heart failure has been observed, suggesting the critical initial 
compensatory role of MCT1 in transporting lactate as a metabolic resource in the failing heart37.
Finally, the assembly of cytochrome c oxidase in the mitochondria is clearly essential for mature cellular respi-
ration and aerobic metabolism in bacteria and eukaryotes38. COX20, an inner mitochondrial membrane protein, 
has been shown to play an important role in organizing efficient cytochrome c oxidase assembly, functioning as 
a chaperone for the process39. Specifically, the hydrophilic domains of COX20 have been shown to be required 
Etiology
Patient 
code Gender
Age at 
transplant 
(years)
EF 
(%)
Duration 
of HF 
(months)
Hb 
(g/L)
eGFR (mL/
min/1.73 m2)
Medications (1 = yes; 0 = no)
ACEi/ARB
Beta-
blocker MRA
ICM
ICM1 M 55 22 73 129 59 1 1 1
ICM2 M 62 24 64 130 54 1 1 1
ICM3 F 51 19 58 123 73 1 1 1
DCM
DCM1 M 51 15 60 122 71 1 1 1
DCM2 M 45 25 75 134 63 1 0 1
DCM3 F 55 29 81 131 79 1 1 0
NFC
NFC1 F 42 — — — — — — —
NFC2 M 38 — — — — — — —
NFC3 M 54 — — — — — — —
Table 1. Patient baseline and clinical characteristics. EF, ejection fraction; Hb, hemoglobin; eGFR, estimated 
glomerular filtration rate; ACEi/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; 
MRA, mineralcorticoid receptor antagonist.
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Fig. 10 FAM162A, MCT1, and COX20 protein expression levels in human adult DCM and ICM heart failure 
patients. (a) Immunoblot analysis of FAM162A, MCT1, and COX20 in human adult DCM and ICM patient 
samples. Right panel, densitometric quantification of the blots. Significantly higher levels of FAM162A in 
human adult DCM and ICM patients, and significantly reduced levels of MCT1 and COX20 protein expression 
in ICM patients were measured. (b) Immunoblot analysis of FAM162A, MCT1, and COX20 in region-
specific infarcted hearts. Right panel, densitometric quantification of the blots. All immunoblots shown are 
representative of at least 3 total immunoblots performed, n = 3 independent biological replicates. Original 
uncropped immunoblots are provided in Supplemental Fig. 9. Asterisks indicate a statistically significant 
p value in a Tukey’s multiple comparison analysis where *p < 0.05 and **p < 0.01; data are presented as 
mean ± SEM. All source data input and analyzed output files were uploaded to figshare (https://doi.org/10.6084/
m9.figshare.11844972.v12).
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for interactions with COX2 and COX18, two conserved subunits of the cytochrome c oxidase complex, to ensure 
successful assembly and respiratory growth39. Furthermore, mutations in human COX20 have been linked to loss 
of neurological control of muscle movements resulting in muscle hypotonia and dystrophy40,41. However, the phe-
notypic spectrum of COX20 expression alterations has not been investigated to date despite its high expression 
levels in the ventricle in the heart.
Elucidating the complete membrane proteome of cardiomyocytes furthers our understanding of myocyte 
biology in both the healthy and diseased heart. Our in-depth membrane proteomic analyses followed by in vitro 
validation in functional adult mouse cardiomyocytes as well as detailed immunoblot analysis from human heart 
biopsies have provided compelling evidence and suggested a link between these previously uncharacterized, 
cardiac-enriched membrane proteins to heart disease progression in the human heart. However, it is important 
to acknowledge that abundance may not be a sufficient indicator of translational significance in function. In 
this study, we have prioritized candidate proteins that show cardiac enrichment as a first step in characteriz-
ing previously understudied cardiac membrane-associate proteins. The role and contribution of many of the 
non-cardiac-enriched candidate proteins, with no previous reported cardiac phenotype shown in Supp. 3, will 
likely be clarified with detailed future studies.
Furthermore, we have characterized their subcellular localization and expression patterns in the myocyte and 
performed detailed, region-specific protein expression analysis in dilated cardiomyopathy and ischemic cardio-
myopathy. Detailed comparison of the dynamic regional subgroups, such as non-infarct, peri-infarct, and infarct 
regions of the ischemic hearts provides key insights into understanding the basis and transition between healthy 
and diseased myocardium. A marked increase in FAM162A expression level in the peri-infarct regions of the 
infarcted hearts suggest its role in the progression of ICM; we speculate where it may be involved in inducing 
mitochondrial apoptosis and thus establishing the pathological phenotypes in response to ischemic insults in the 
heart. Similarly, an upregulation of FAM162A in human DCM hearts suggests its specific role in modulating the 
etiologies of this specific heart disease characterized by dilated and impaired ventricular contraction. Defects in 
mitochondrial proteins in the heart are a frequent cause of cardiac myopathies as cardiomyocytes are mitochon-
dria enriched and the myocyte relies on the mitochondria to generate sufficient ATP to fuel beat-to-beat con-
tractions. Future studies investigating the therapeutic potential of FAM162A depletion in the failing heart would 
thus be invaluable. Moreover, a near complete deletion of MCT1 expression in infarcted hearts- irrespective of 
ventricular region- may indicate a crucial importance in maintaining normal cardiac physiology and its direct 
contribution to ICM. However, the specific mechanisms will require ongoing investigations, with future condi-
tional, tissue-specific knockout studies in the heart providing immeasurable insights and quality control into their 
specific roles in regulating heart function. Until then, ongoing work will continue refine the role of FAM162A, 
MCT1, and COX20 in the heart.
Lastly, it is important to acknowledge that this study is primarily explorative and observational in its nature. 
Obviously, future studies must focus on the precise molecular functions of these identified proteins in cardiac 
health and disease to determine their specific role(s) in regulating heart development and/or function. Moreover, 
although we attempted necessary controls where possible, antibody-based experiments should always be assessed 
and interpreted very carefully. The antibodies used in this study were carefully selected, with previous validations 
for specificity, however, accuracy of these subcellular localization data of FAM162A, MCT1, and COX20 in car-
diomyocytes depend largely on the quality of the primary antibodies used in our confocal studies. Despite such 
limitations, our co-immunofluorescence studies with known mitochondrial and plasma membrane markers and 
consistent data from three-dimensional reconstructive imaging analysis along with high sample numbers were 
designed to minimize any potential confounding factors in these studies.
Taken together, our study represents an integrated analysis of cardiomyocyte cell surface proteome to elucidate 
promising novel membrane candidates of heart function and potential therapeutic targets for heart disease. Our 
human and mouse cardiomyocyte membrane proteomes can be used as a reference for future studies aiming to 
identify and characterize heart disease markers and therapeutic targets for heart failure. Future deep membrane 
proteomics studies of cardiomyocytes with combined proteomic investigations of cardiac membrane protein 
PTM (post-translational modifications) will help complete the membrane proteome of the human heart and 
provide molecular mechanistic insights into the various disease etiologies of heart failure.
Methods
Cell-surface membrane proteome and identification of previously uncharacterized, evolutionarily conserved, 
cardiac-enriched membrane proteins. Previously, we enriched for membrane fractions from mouse neonatal ven-
tricular cardiomyocytes and human fetal cardiomyocytes using cationic colloidal silica beads10,11. In those exper-
iments, a membrane-depleted homogenate (removed after centrifugation at 1000 g for 5 min, labelled ‘H’) as well 
as a membrane-enriched fraction (pellet resuspended in NET buffer (400 mM NaCl, 25 mM Hepes pH7.4, and 
1% Triton-X100) for 2 hours at 4 °C). were then subjected MudPIT42 (Multidimensional Protein Identification 
Technology) analysis with stringent statistical filtering (<1% false discovery rate) as previously described10. This 
analysis resulted in the identification of 2,762 human and 3,033 mouse proteins. The original raw mass spec-
trometry files were searched using X!TANDEM (version 2010.12.01.1; ftp://ftp.thegpm.org/projects/tandem/
source/2010-12-01/) against human or mouse UniProt database (version 2011_03; ftp://ftp.uniprot.org/pub/
databases/uniprot/previous_releases/release-2011_01/) with the following search parameters: Parent ion Δ-mass 
of 4 Da, fragment mass error of 0.4 Da, and complete carbaminomethyl modification of cysteine by iodoacetic 
acid. The resulting tryptic peptides matching these criteria made up the final list of identified proteins. Next, 
to identify conserved membrane-associated proteins, orthology mapping analysis of all identified human and 
mouse proteins was performed using the MGI orthology database (http://www.informatics.jax.org) taking into 
account only one-to-one orthology to yield the identification of human and mouse one-to-one orthologues43. 
1 6Scientific Data |           (2020) 7:425  | https://doi.org/10.1038/s41597-020-00762-1
www.nature.com/scientificdatawww.nature.com/scientificdata/
Comparative proteomics analysis using Qspec identified proteins that were enriched in the TX-100 fraction com-
pared to the homogenate fraction, resulting in the identification of the membrane-enriched orthologue proteins 
(Supplementary Table 1).
The identified 555 proteins were converted to 550 as 5 IDs (TFRC_human P02786, mouse Q62351; 
TIMM50_human Q3ZCQ8, mouse Q9D880; PSPC1_human Q8WXF1, mouse Q8R326; GNAS_human P84996, 
mouse Q6R0H6; TMPO_humanP42167, mouse Q61029) were amalgamated into unique IDs. To rank the 550 
membrane-enriched proteins identified, we first carried out prediction of transmembrane domains of the 550 
identified proteins using TMHMM version 2 (http://www.cbs.dtu.dk/services/TMHMM) to identify membrane 
localized protein clusters. To further select novel cardiac membrane-enriched proteins, MGI phenotypic analysis 
(http://www.informatics.jax.org/phenotypes.shtml) was performed to individually map against our datasets to 
select and rank novel cardiac membrane proteins. Finally, we manually annotated the 550 protein clusters to select 
cardiac enriched transcripts by employing the publicly available microarray database, BioGPS microarray data 
(http://biogps.org/) to complete the rank ordered analysis of the 550 identified proteins. Excel output file con-
taining full ranking criteria along with step-by-step ranking of the 550 identified proteins (labelled as “Ranking 
Criteria + Step-by-step ranking) was uploaded to figshare (https://doi.org/10.6084/m9.figshare.11844972.v12).
Human myocardium procurement. Cardiac tissue samples were collected from donors with no history of 
heart disease and patients with dilated cardiomyopathy or ischemic heart disease during their cardiac transplan-
tation through the HOPE program (Human Organ Procurement and Exchange program, University of Alberta, 
Edmonton, Canada) and the Human Explanted Heart Program (HELP) respectively under the approval of the 
Human Research Ethics Board at the University of Alberta44,45. Specifically, following cold cardioplegia, myocar-
dial samples were excised from the left ventricular anterior free wall and immediately flash-frozen to be stored 
at −140 °C. Clinical review of 12-lead ECG and coronary angiogram were used to identify the infarct, peri-, and 
non-infarct regions of the left ventricle in ischemic heart disease patients. Patient samples from each category 
(Non-failing control; n = 3, ICM; n = 3, DCM; n = 3) were collected and used in this study. Patient baseline and 
clinical characteristics including age, gender, duration of heart failure, ejection fraction, hemoglobin levels, eGFR, 
and medication history are presented in Table 1.
Adult and neonatal mouse cardiomyocyte isolation. All experimental procedures involving animals 
were approved by the University of Toronto Animal Use and Care Committee; all animal experiments were con-
ducted in accordance with the animal care guidelines. Adult mouse ventricular cardiomyocytes were isolated 
from adult male 6–8 week old CD1 mice (Jackson Labs)46,47. The outbred CD1 mouse strain was used due to their 
genetic diversity, larger litter size, and we have used these stains in our ongoing research programs where we have 
refined cardiomyocyte isolation from CD1 mouse hearts for in vitro genetic and small-molecule manipulation 
in our lab47. Briefly, mice were euthanized with isoflurane and hearts perfused with EDTA buffer containing 15 
μmol/L of blebbistatin with the heart clamped at the ascending aorta, followed by tissue digestion with colla-
genase type II (525 units/mL; Worthington Biochemical Corp.). The isolate was then filtered through a 70μm 
strainer and gravity-settled for 15 min to allow rod-shaped cardiomyocytes to settle by gravity and form a pel-
let. Dissociated ventricular cardiomyocytes were seeded on Geltrex-coated glass-bottom dishes for subsequent 
experiments. Primary neonatal mouse ventricular cardiomyocytes were isolated and cultured from 1–3 day old 
CD1 pups as described previously46. Isolated ventricles were enzymatically digested in 0.05% trypsin overnight at 
4 °C, followed by collagenase type II digestion (450 units/mL) at 37°C. Collected ventricular cardiomyocytes were 
seeded and maintained on gelatin-coated glass-bottom dishes for 48 hours prior to any experiments.
Publicly available RNASeq and proteomic datasets. Publicly available data sources of mRNA 
Affymetrix transcript data from the GEO Profiles in NCBI including several mouse and human heart diseases 
were downloaded and analyzed. FAM162A: 2d, 10d, 21d TAC (GPL81, 160218_at), MI (GPL5371, 20160), 
alpha-tropomyosin mild HCM (GPL339, 1451385_at), Emery-Dreifuss cardiomyopathy (GPL1261, 1443339_at), 
heart transplant (GPL96, 220942_x_at), Inflammatory DCM (GPL570, 220942_x_at), DCM (GPL6244, 
8082066), and idiopathic and ischemic cardiomyopathies (GPL570, 220942_x_at); MCT1/SLC16A1: Severe 
DCM (GPL32, 101588_at), 2d, 10d, 21d TAC (GPL81, 101588_at), MI (GPL5371, 12952), alpha-tropomyosin 
mild HCM (GPL339, 1415802), Emery-Dreifuss (GPL1261, 1415802), heart transplant (GPL96, 202235), 
Inflammatory DCM (GPL570, 202235_at), DCM (GPL6244, 7918622), and idiopathic and ischemic cardi-
omyopathies (GPL570, 1557918_s_at); COX20: 2d, 10d, 21d TAC (GLP81, 160315_at), MI (GPL5371, 1309), 
alpha-tropomyosin mild HCM (GPL339, 1428619_at), Emery-Dreifuss (GPL1261, 1428619_at), heart trans-
plant (GPL96, 206848_at), Inflammatory DCM (GPL570, 224820_at), DCM (GPL6244, 7911085), and idio-
pathic and ischemic cardiomyopathies (GPL570, 224820_at). Data were reported as normalized hybridization 
signals. Comprehensive RNA-Seq based transcript levels of multiple mouse organs were obtained from the 
Human Protein Atlas26. Data were reported as the abundance in ‘Transcripts per Million’ (TPM) in the heart, 
relative to the sum of the TPM values across all tissues26. All source data input and analyzed output files (labelled 
as “Fig. 3_Cardiac-enriched + noMGI”, “Fig. 9 GEO profiles raw data”, “Supp. 1_HPM raw data”, “Supp. 2_
Cardiac-enriched + MGI”, “Supp. 3_Noncardiac-enriched + noMGI”, “Supp. 4_Noncardiac-enriched + MGI”, 
“Supp. 5_HPM raw data”, and “Supp. 7_HPM raw data”) were uploaded to figshare (https://doi.org/10.6084/
m9.figshare.11844972.v12).
To assess the subcellular localization in subcellular organelles in the heart, we utilized immunohistochem-
ical data available in the Human Protein Atlas26 to investigate their protein distributions and expression pat-
terns in healthy human ventricular tissues. Images for proteins were downloaded from the Atlas which contains 
images of histological sections from normal and cancer tissues. Specific antibodies were labeled with DAB 
(3,3’-diaminobenzidine) with a resulting brown staining indicative of antibody reactivity, with counterstained 
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hematoxylin to enable visualization of nuclei. Images were all available at https://www.proteinatlas.org/human-
proteome/tissue/heart26, and images used in Fig. 4 were uploaded (labelled as “Fig. 4_HPA original uncropped 
images”) to figshare (https://doi.org/10.6084/m9.figshare.11844972.v12).
Antibodies and reagents. Primary rabbit polyclonal anti-FAM162A antibody (PA5-24470, ThermoFisher; 
IB: 1:1000 dilution, IF: 1:800 dilution), rabbit polyclonal anti-COX20 antibody (25752-I-AP, Proteintech; IB: 
1:1000 dilution, IF: 1:200 dilution), mouse monoclonal anti-MCT1 antibody (MA5-18288, ThermoFisher; IB: 
1:1000 dilution, IF: 1:500 dilution) and rabbit polyclonal anti-MCT1 antibody (PA5-72957; ThermoFisher; IB: 
1:1000 dilution, IF: 1:500 dilution) were used for immunofluorescence and immunoblot studies. These antibodies 
were carefully selected where previous validation data have been reported. Specifically, the MCT1 antibody was 
validated in CRISPR/Case9 siRNA-mediated knockdown HEK293 cells where a complete depletion of MCT1 
expression was observed in immunoblot analysis (ThermoFisher, P14612), the COX20 antibody was validated 
in immunohistochemistry and immunofluorescence studies of various human tissues and cell lines (Proteintech, 
25752-1-AP), and lastly, the FAM162A antibody was validated in immunoblot experiments where a clear protein 
band was detected at the expected molecular weight with minimal nonspecific bands (ThermoFisher, PA5-24470). 
The following immunogen sequences for the abovementioned commercially available antibodies are indicated in 
Fig. 6d–f: peptide sequence between 118–146 amino acids from the C-terminal region of human FAM162A; 
peptide fragment within amino acids 436–500 of human MCT1; peptide sequence corresponding to amino acids 
1–118 amino acids of human COX20. Additionally, primary mouse monoclonal anti-COX IV antibody (ab14744, 
abcam; IF: 1:1000 dilution) and rabbit polyclonal anti-Gαi antibody (#21006, NewEast Biosciences; IF: 1:800 
dilution) were used for immunofluorescence co-staining studies. Lastly, mouse anti-alpha actin antibody (JLA20, 
DSHB) was used for immunoblot studies at 1:1000 dilution.
Similarly, antibody sensitivity and specificity are of essential importance in ensuring correct interpretations 
for expression patterns in healthy human myocardial tissues presented in Fig. 4a. All antibodies used for the 
presented immunohistochemistry data were validated previously where a unique protein epitope signature tag 
with high specificity was selected for each antibody used in immunohistochemistry studies followed by immu-
noblot analysis from limited tissues (liver, tonsil) and cell lines (RT4, U-251 MG). Finally, the observed staining 
pattern was assigned a reliability score based on concordance with experimental protein characterization in the 
UniProt database48,49. In addition to the standard antibody validation procedures, enhanced antibody validation 
was performed for MCT1, TLN2, MSN, FLOT1, DYSF, AOC3, CTNND1, LAMA2, BGN, MYH7, TNNT2, and 
TNNI3 antibodies where genetic and orthogonal validations were performed to confirm antibody specificity for 
immunohistochemistry assays.
Immunoblot analysis. Protein lysates from mouse tissues were harvested in radioimmunoprecipitation 
assay buffer (RIPA) (50 mM Tris-HCl; pH7.4, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 
and 2 mM EDTA), supplemented with EDTA-free protease inhibitor cocktail (Roche), for 30 minutes on ice, 
spun down at 15,000 × g at 4 °C as previously described50. Human myocardium samples were harvested in 8 M 
urea supplemented with protease and phosphatase inhibitor cocktails (Roche) and spun down at 15,000xg at 
4°C for 15 minutes to remove tissue debris. Soluble fractions (supernatant) were then saved for immunoblotting 
studies. Standard SDS-PAGE chemiluminescent analysis was performed and tissue lysates were run on 10–12% 
polyacrylamide gels and transferred onto 0.45μm nitrocellulose membranes. Primary antibodies were added after 
blocking with 5% milk in 0.05% TBS-Tween20 for 1 hour and incubated at 4°C overnight. Secondary antibodies 
of anti-mouse (W402B, Promega) and anti-rabbit (W401B, Promega) HRP-conjugated IgG were used to at 1:2500 
dilution. Original uncropped immunoblots are available and provided as Supplemental Fig. 9. Immunodepletion 
experiments were performed by incubating primary antibodies with 10 μg of purified cMyc/DDK-tagged human 
FAM162A (Origene, LY415331), cMyc/DDK-tagged human MCT1 (Origene, LY401069), or cMyc/DDK-tagged 
human COX20 (Origene, LY405090) lysates in 10 mL of 5% milk (1μg /mL) for 3 hr at 4°C prior to probing the 
membrane at 4°C overnight.
Immunofluorescence and confocal microscopy. Acutely isolated adult mouse ventricular cardiomy-
ocytes and cultured neonatal mouse ventricular cardiomyocytes were seeded on imaging glass-bottom dishes 
(MatTek, MA, USA) for immunofluorescence analysis. All immunofluorescence procedures were performed 
as described previously46. Briefly, cardiomyocytes were fixed with 4% paraformaldehyde for 30 minutes for 
adult cardiomyocytes and 15 minutes for neonatal cardiomyocytes on ice followed by permeabilization with 
0.5% Triton X-100, 0.2% Tween-20, and 5% FBS in PBS) for 30 minutes at room temperature. Cardiomyocytes 
were then incubated with primary antibodies in permeabilization overnight at 4°C. Samples were then incu-
bated with fluorophore-conjugated secondary antibodies the next day (Alexa Fluor 488 or Alexa Fluor 647, 
Molecular Probes) at 1:1000 dilution. Samples were visualized using a Zeiss spinning-disk confocal microscope. 
Immunodepletion experiments were performed by incubating primary antibodies with 2 μg of purified cMyc/
DDK-tagged human FAM162A (Origene, LY415331), cMyc/DDK-tagged human MCT1 (Origene, LY401069), 
or cMyc/DDK-tagged human COX20 (Origene, LY405090) lysates in 1 mL of permeabilization buffer for 3 hr at 
4°C prior to incubating cardiomyocytes with primary antibodies at 4°C overnight.
Image processing and analysis. Image processing and analysis of acquired images were performed 
using the Zeiss ZEN software (ZEN 2012 blue edition). Specifically, the unsharp masking tool was applied to all 
exported images to enhance subtler structures using ‘auto-thresholding’. All three-dimensional reconstructive 
analysis of z-stack images were performed using Imaris 8.1 (Bitplane, Switzerland). Three-dimensional recon-
struction and co-localization models were built using surpass surface reconstruction, an intensity-based render-
ing of three-dimensional volume of z-stack images with ‘auto-thresholding’ set at Pearson’s coefficient p > 0.5.
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Experimental design and statistical rationale. Searched mass spectrometry data was downloaded from 
Sharma et al.10, whereby three independent biological replicates including three technical replicates within each 
biological replicate were used for further informatic analyses. For GEO RNA-Seq and immunoblot studies, statis-
tical analyses were analyzed using the GraphPad Prism 8 software. Descriptive statistics are reported and shown 
as mean ± SEM. All bar graphs showing individual data points with error bars are graphically presented using the 
GraphPad Prism 8 software. Normally distributed data were analyzed using one-way ANOVA followed by post hoc 
Tukey’s multiple comparison test for each mean comparison. Experimental mean-fold protein intensities, relative 
to controls from triplicate assays, were considered different from controls at the p ≤ 0.05 significance level. For 
visual representation, a p value ≤ 0.05 is denoted by *; a p value ≤ 0.01 is denoted by **, and a p value ≤ 0.001 
is denoted by ***. All immunoblots shown are representative from a minimum of three independent biological 
replicates; all original uncropped immunoblots are provided in Supplemental Fig. 9. All data figures and tables as 
well as all supporting information were uploaded to figshare (https://doi.org/10.6084/m9.figshare.11844972.v12).
Data availability
All data records and supporting materials have been deposited in proteomeXchange and figshare. Specifically, 
MudPIT excel output files obtained from the Supplementary Table files of Sharma et al.10 containing original 
unique peptides and total spectra detected files (labelled as “Sharma et al. ncomms_2015_peptides and spectra in 
human ventricular cardiomyocytes” and “Sharma et al. ncomms_2015_peptides and spectra in mouse ventricular 
cardiomyocytes”) were uploaded to figshare (https://doi.org/10.6084/m9.figshare.11844972.v12)51. Additionally, 
all excel source input and analyzed output files including original uncropped images were uploaded to figshare 
(https://doi.org/10.6084/m9.figshare.11844972.v12)51. Lastly, the original step-by-step raw mass spectrometry 
proteomics data for each biological replicate of mouse and human cardiomyocytes including both homogenate 
(labelled ‘H’) and membrane enriched (labelled TX-100 for human and NET for mouse) fractions were deposited 
to the ProteomeXchange Consortium with the dataset identifier (PXD017732)52.
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